# US 2025/0369014 A9 · Site-specific integrating recombinant aav vectors for gene therapy and improved production methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0369014 A9
- Document ID: US20250369014A9
- Status: Published application
- Kind: A9
- Application number: 18/884,901
- Filed: 2024-09-13
- Published: 2025-12-04
- Earliest claimed: 2015-02-19
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Arun Srivastava; Chen Ling
- Web page: https://patentgrep.com/patent/US20250369014A9

## CPC

- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods of site-specific integration of a heterologous sequence into a host genome (e.g., by administering a recombinant adeno-associated virus (rAAV) to a host cell in the presence of a Rep protein), and methods for treating diseases and disorders by delivering an rAAV that comprises a nucleic acid vector comprising a Rep protein. Also provided herein are methods and compositions for producing rAAV particles with improved titer and transduction efficiencies.

## Claims

### Claim 1

A method of promoting site-specific nucleic acid integration into a host genome, the method comprising: delivering a recombinant adeno-associated virus (rAAV) particle comprising a nucleic acid vector to a host cell in the presence of a Rep protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nucleic acid vector comprises AAV2 inverted terminal repeats (ITRs) or AAV6 ITRs.

### Claim 3 (depends on 1)

The method of claim 1, wherein rAAV particle is a AAV6 particle.

### Claim 4 (depends on 1)

The method of claim 1, wherein the host cell is a human cell.

### Claim 5 (depends on 4)

The method of claim 4, wherein the host cell is a stem cell.

### Claim 6 (depends on 5)

The method of claim 5, wherein the host cell is a liver, muscle, brain, eye, pancreas, kidney, or hematopoietic stem cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the host cell is ex vivo.

### Claim 8 (depends on 1)

The method of claim 1, wherein the host cell is in situ in a host.

### Claim 9 (depends on 1)

The method of claim 1, wherein the nucleic acid vector encodes the Rep protein.

### Claim 10 (depends on 1)

The method of claim 1, wherein the Rep protein is delivered to the host cell separately from the nucleic acid vector.

### Claim 11 (depends on 1)

The method of claim 1, wherein the Rep protein is expressed from a second nucleic acid that is delivered to the host cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second nucleic acid is an mRNA that is transiently transfected into the host cell.

### Claim 13 (depends on 11)

The method of claim 11, wherein the second nucleic acid is transfected into the host cell in a viral particle.

### Claim 14 (depends on 1)

The method of claim 1, wherein the nucleic acid vector encodes a therapeutic protein.

### Claim 15 (depends on 14)

The method of claim 14, wherein the therapeutic protein is human β-globin.

### Claim 16 (depends on 1)

The method of claim 1, wherein the Rep protein is an AAV2 or AAV6 Rep protein.

### Claim 17 (depends on 3)

The method of claim 3, wherein the AAV6 particle comprises a modified capsid protein comprising a non-tyrosine residue at a position that corresponds to a surface-exposed tyrosine residue in a wild-type AAV6 capsid protein, a non-threonine residue at a position that corresponds to a surface-exposed threonine residue in the wild-type AAV6 capsid protein, a non-lysine residue at a position that corresponds to a surface-exposed lysine residue in the wild-type AAV6 capsid protein, a non-serine residue at a position that corresponds to a surface-exposed serine residue in the wild-type AAV6 capsid protein, or a combination thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the modified capsid protein comprises a non-tyrosine residue and/or a non-threonine residue at one or more of or each of Y705, Y731, and T492 of a wild-type AAV6 capsid protein.

### Claim 19 (depends on 18)

The method of claim 18, wherein the non-tyrosine residue is phenylalanine and the non-threonine residue is valine.

### Claim at position 20

20-35. (canceled)
